LAS VEGAS–(EINPRESSWIRE)-Evoq Technologies (evoqtechnologies.com) today announced a major milestone for eye care, confirming that its innovative diagnostic device, Twilight™, is officially registered and listed with the U.S. Food and Drug Administration (FDA) as a Class I medical device and is now available for sale in the United States.

LAS VEGAS–(EINPRESSWIRE)–Twilight debut at ARVO 2025, launch of investigator-led studies, and Innovation Hub showcase at AAO highlight impact of Evoq’s team-driven mission.

LAS VEGAS–(EINPRESSWIRE)– Evoq Technologies is showcasing its next-generation diagnostic tools at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, (SLC Convention Center May 4-7) focused on solving the global shortage in eye care services by delivering accessible, patient-friendly technologies for early retinal disease detection.

LAS VEGAS–(BUSINESS WIRE)–The newly released Evoq Smartphone-Based Electrophysiology System represents a revolutionary, cost-effective alternative to legacy desktop devices. The Evoq system is tailored to meet the needs of MD, OD, PhD, DVM, researchers, and technologists who are advancing the art and science of evoked response electrophysiology — for vision, auditory, neurology, and physical therapy.

LAS VEGAS–(BUSINESS WIRE)–Evoq Technologies is excited to announce the FDA registration of the first in its family of products based on its proprietary smartphone-based biosensor technology. Dubbed the “SmartERG^®” Platform, it’s built to test the eye’s retinal health in unique ways.

LAS VEGAS–(EINPRESSWIRE)–Evoq Technologies is introducing the SightGard platform, a suite of tools designed to help eye care professionals detect retinal diseases such as macular degeneration and diabetic retinopathy earlier than ever before.